ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Clinical impact of amyloid PET in memory clinic: A 2-year longitudinal real-world study in Taiwan.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLongitudinal evidence on amyloid positron emission tomography (PET) for Alzheimer's disease (AD) diagnosis in Taiwan and Asian memory clinics remains limited. This study evaluated the diagnostic and prognostic impact of florbetaben PET in a Taiwanese cohort.
methodsThis prospective cohort study enrolled 206 memory clinic participants who underwent florbetaben amyloid PET, volumetric magnetic resonance imaging, apolipoprotein E genotyping, and neuropsychological assessment, with 2-year longitudinal follow-up.
resultsAmyloid positivity was present in 48% of participants and drove diagnostic reclassification in 49.5% of the cohort. Receiver operating characteristic curve analysis identified an optimal Centiloid (CL) threshold of 21.60 (sensitivity 91.18%, specificity 99.04%, area under the curve [AUC] = 0.98). Amygdala, inferior parietal, and superior temporal atrophy were strong structural predictors of amyloid positivity (AUC = 0.79). DISCUSSION: These findings establish a locally validated amyloid threshold and provide actionable diagnostic and prognostic stratification in a real-world Asian memory clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.